scholarly journals Core binding factor acute myeloid leukaemia and c-KIT mutations

2013 ◽  
Vol 29 (5) ◽  
pp. 1867-1872 ◽  
Author(s):  
LUDOVICA RIERA ◽  
FILIPPO MARMONT ◽  
DANIELA TOPPINO ◽  
CHIARA FRAIRIA ◽  
FRANCESCA SISMONDI ◽  
...  
2012 ◽  
Vol 36 (11) ◽  
pp. 1330-1333 ◽  
Author(s):  
Edouard Cornet ◽  
Florent Dumézy ◽  
Christophe Roumier ◽  
Pascale Lepelley ◽  
Nathalie Jouy ◽  
...  

2003 ◽  
Vol 123 (5) ◽  
pp. 819-829 ◽  
Author(s):  
G.-A. Banat ◽  
Kerstin Ihlow ◽  
Nurguel Usluoglu ◽  
Sabine Hoppmann ◽  
Marianne Hoeck ◽  
...  

Author(s):  
Naeem Jabbar ◽  
Neelum Mansoor ◽  
Sidra Maqsood ◽  
Zaid Muhammad Aslam ◽  
Anzal Taufeeq Jangda ◽  
...  

Abstract Objective: To find the frequency of core binding factor acute myeloid leukaemia in our population, and to determine its association with morphological subtypes. Methods: The retrospective study was conducted at The Indus Hospital, Karachi, and comprised data of patients aged 1-17 years who were diagnosed with acute myeloid leukaemia from July 2013 to June 2017. Data was analysed using SPSS 21. Results: Of the 237 patients, 137(58%) were males and 100(42%) were females. The overall mean age was 8±4.34 years. Cytogenetic testing had been performed in 212(89.45%) cases, and core binding factor was detected in 72(34%) cases. There was significant difference between the mean values of white cell count and the subtypes (p=0.000). Also the difference between core binding factor and the subtypes was significant (p=0.000). Conclusion: There was found to be a significant association of core binging factor with specific subgroups of acute myeloid leukaemia. Key Words: Acute myeloid leukaemia, Core binding factor, Cytogenetic abnormalities, Prognosis. Continuous....


2006 ◽  
Vol 135 (2) ◽  
pp. 165-173 ◽  
Author(s):  
Frederick R. Appelbaum ◽  
Kenneth J. Kopecky ◽  
Martin S. Tallman ◽  
Marilyn L. Slovak ◽  
Holly M. Gundacker ◽  
...  

2019 ◽  
Vol 12 (2) ◽  
pp. bcr-2018-225680 ◽  
Author(s):  
Talal Alzahrani ◽  
Abdulelah Nuqali ◽  
Nejat Naser ◽  
Amar R Jariwala

We present a patient with Crohn’s disease under treatment with adalimumab who developed acute myeloid leukaemia (AML) with core-binding factor beta gene rearrangement. This case report emphasises the importance of long-term close follow-up of patients receiving adalimumab because of the increased risk of developing AML and other malignancies.


Sign in / Sign up

Export Citation Format

Share Document